These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34961633)

  • 1. A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults.
    Drazan D; Czajka H; Maguire JD; Pregaldien JL; Maansson R; O'Neill R; Anderson AS; Balmer P; Beeslaar J; Perez JL
    Vaccine; 2022 Jan; 40(2):351-358. PubMed ID: 34961633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
    Peterson J; Drazan D; Czajka H; Maguire J; Pregaldien JL; Seppa I; Maansson R; O'Neill R; Balmer P; Jodar L; Jansen KU; Anderson AS; Perez JL; Beeslaar J
    Lancet Infect Dis; 2023 Dec; 23(12):1370-1382. PubMed ID: 37579773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
    Vesikari T; Østergaard L; Beeslaar J; Absalon J; Eiden JJ; Jansen KU; Jones TR; Harris SL; Maansson R; Munson S; O'Neill RE; York LJ; Perez JL
    Vaccine; 2019 Mar; 37(12):1710-1719. PubMed ID: 30770221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months.
    Østergaard L; Vesikari T; Senders SD; Flodmark CE; Kosina P; Jiang HQ; Maguire JD; Absalon J; Jansen KU; Harris SL; Maansson R; Balmer P; Beeslaar J; Perez JL
    Vaccine; 2021 Jul; 39(32):4545-4554. PubMed ID: 34215452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studies.
    Marshall HS; Vesikari T; Richmond PC; Wysocki J; Szenborn L; Beeslaar J; Maguire JD; Balmer P; O'Neill R; Anderson AS; Prégaldien JL; Maansson R; Jiang HQ; Perez JL
    Lancet Infect Dis; 2023 Jan; 23(1):103-116. PubMed ID: 36087588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults.
    Ostergaard L; Vesikari T; Absalon J; Beeslaar J; Ward BJ; Senders S; Eiden JJ; Jansen KU; Anderson AS; York LJ; Jones TR; Harris SL; O'Neill R; Radley D; Maansson R; Prégaldien JL; Ginis J; Staerke NB; Perez JL;
    N Engl J Med; 2017 Dec; 377(24):2349-2362. PubMed ID: 29236639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies.
    Beeslaar J; Absalon J; Anderson AS; Eiden JJ; Balmer P; Harris SL; Jones TR; O'Neill RE; Pregaldien JL; Radley D; Maansson R; Ginis J; Srivastava A; Perez JL
    Infect Dis Ther; 2020 Sep; 9(3):641-656. PubMed ID: 32700260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci.
    Harris SL; Tan C; Andrew L; Hao L; Liberator PA; Absalon J; Anderson AS; Jones TR
    Vaccine; 2018 Oct; 36(45):6867-6874. PubMed ID: 30269916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of expanded
    Borrow R; Martinón-Torres F; Abitbol V; Andani A; Preiss S; Muzzi A; Serino L; Sohn WY
    Expert Rev Vaccines; 2023; 22(1):738-748. PubMed ID: 37622470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling persistence of hSBA titers over time following a primary series and a booster dose of MenB-FHbp.
    Cai B; Peyrani P; Beeslaar J; Burman C; Balmer P
    Vaccine; 2023 Apr; 41(17):2729-2733. PubMed ID: 37024411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
    Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.
    Lujan E; Partridge E; Giuntini S; Ram S; Granoff DM
    Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28566335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
    Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
    BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MenB-FHbp Meningococcal Group B Vaccine (Trumenba
    Shirley M; Taha MK
    Drugs; 2018 Feb; 78(2):257-268. PubMed ID: 29380290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.
    Perrett KP; McVernon J; Richmond PC; Marshall H; Nissen M; August A; Percell S; Toneatto D; Nolan T
    Vaccine; 2015 Sep; 33(39):5217-24. PubMed ID: 26232542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.
    Burman C; Alderfer J; Snow VT
    J Clin Pharm Ther; 2020 Apr; 45(2):270-281. PubMed ID: 31820483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and Safety of Investigational MenABCWY Vaccine and of 4CMenB and MenACWY Vaccines Administered Concomitantly or Alone: a Phase 2 Randomized Study of Adolescents and Young Adults.
    Beran J; Dražan D; Enweonye I; Bhusal C; Toneatto D
    mSphere; 2021 Dec; 6(6):e0055321. PubMed ID: 34787449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine.
    Pajon R; Lujan E; Granoff DM
    Vaccine; 2016 Jan; 34(5):643-649. PubMed ID: 26709637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial.
    Davis K; Valente Pinto M; Andrews NJ; Goldblatt D; Borrow R; Findlow H; Southern J; Partington J; Plested E; Patel S; Holland A; Matheson M; England A; Hallis B; Miller E; Snape MD
    Lancet Infect Dis; 2021 May; 21(5):688-696. PubMed ID: 33428870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine in healthy adolescents in Korea--A randomised trial.
    Lee HJ; Choe YJ; Hong YJ; Kim KH; Park SE; Kim YK; Oh CE; Lee H; Song H; Bock H; Casula D; Bhusal C; Arora AK
    Vaccine; 2016 Feb; 34(9):1180-6. PubMed ID: 26826544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.